Table 3.
Mechanism of anti-obesity drugs acting in the central nervous system
| Drug name | Mechanism |
|---|---|
| Phentermine, diethylpropion, benzphetamine, and phendimetrazine | norepinephrine release with minor dopamine release |
| Bupropion/naltrexone | Stimulates dopamine and POMC neurons and blocks inhibitory feedback to mu opioid receptor on POMC neurons |
| Topiramate/phentermine | norepinephrine release, GABA modulation, voltage-gated ion channel modulation, inhibition of AMPA/kainite excitatory glutamate receptors and inhibition of carbonic anhydrase |
| Lorcaserin | Serotonin 2C receptor agonist |
| Lorcaserin-ER | Serotonin 2C receptor agonist |
| Liraglutide | Glucagon-like peptide-1 agonist |
| Drugs in Phase III | |
| Tesofensine | Reuptake inhibitor of serotonin, norepinephrine and dopamine |
ER = Extended Release; POMC = Proopiomelanocortin; GABA = Gamma-Aminobutyric Acid; AMPA = α- amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid